Tasos Konidaris

Tasos is responsible for leading Amneal’s global finance strategies, including oversight for Finance and Accounting, Internal Audit, Investor Relations and Information Technology. He brings more than 30 years of corporate finance and leadership experience, including in the pharmaceutical and business analytics/data industries. Tasos most recently served as Alcresta Therapeutics, Inc.’s Chief Financial Officer from 2016 to 2020, where he led the company’s finance, corporate development, information technology and human resources functions, and was instrumental in supporting the commercialization of a novel therapy to help critically ill patients and expand the company’s R&D pipeline. Prior to that, he served as Executive Vice President, Chief Financial Officer and Head of Corporate Development of Ikaria, Inc., from 2011 to 2015. In that role, he led finance and corporate development functions in delivering robust global organic growth as well as growth through licensing and acquisitions. Before joining Ikaria, Tasos served as Senior Vice President and Chief Financial Officer of Dun & Bradstreet Corporation for seven years, and previously held financial and general management roles of increasing responsibility at Schering-Plough Corporation, Pharmacia Corporation, Novartis Corporation and Bristol-Myers Squibb. He currently serves as a Director on the boards of Kadmon Holdings and Zep Inc. He holds a B.S. in Mathematics and Finance from Gwynedd Mercy University and an M.B.A. from Drexel University.